This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): ABT-279
Description: ABT-279 is a novel dipeptidyl peptidase IV (DPP4) inhibitor. Inhibition of DPP4 increases the amount of circulating active GLP-1, a peptide that increases insulin secretion in a glucose-dependent fashion, thereby lowering blood glucose levels.
Additional information available to subscribers only: